Thiazolidinediones and clinical outcomes in type 2 diabetes.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.Circulation · 2013
   Trial
2. Brain insulin resistance mediated cognitive impairment and neurodegeneration: Type-3 diabetes or Alzheimer's Disease.Acta neurologica Belgica · 2025
   Review
3. Associations between Diabetes Mellitus and Selected Cancers.International journal of molecular sciences · 2024
   Review
4. Diabetes Mellitus and Thyroid Cancers: Risky Correlation, Underlying Mechanisms and Clinical Prevention.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024
   Review
5. Cardiovascular effects of anti-diabetes drugs.Expert opinion on drug safety · 2016
   Review
6. Options for Controlling Type 2 Diabetes during Ramadan.Frontiers in endocrinology · 2016
   Review
7. The diabetic patient in Ramadan.Avicenna journal of medicine · 2014
   Review
8. Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan.Diabetes, metabolic syndrome and obesity : targets and therapy · 2012
   Article
9. Recommendations for management of diabetes during Ramadan: update 2010.Diabetes care · 2010
   Article
10. Impact of rosiglitazone meta-analysis on use of glucose-lowering medications.Open medicine : a peer-reviewed, independent, open-access journal · 2010
    Article
11. When is evidence of lack of harm enough? Has the rosiglitazone controversy ended?Current diabetes reports · 2009
    Article
12. Meta-analysis: A brief introduction.Clinical and translational science · 2009
    Review

Corrections and comments

• Comment on
  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.2009

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as